Get the Stockscreener App
176.93
0.68%
1.19
Jazz Pharmaceuticals Plc stock is traded at $176.93, with a volume of 1.01M.
It is up +0.68% in the last 24 hours and up +28.68% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$175.74
Open:
$175.56
24h Volume:
1.01M
Relative Volume:
1.10
Market Cap:
$10.75B
Revenue:
$4.09B
Net Income/Loss:
$-404.84M
P/E Ratio:
-26.22
EPS:
-6.7469
Net Cash Flow:
$1.24B
1W Performance:
+25.42%
1M Performance:
+28.68%
6M Performance:
+63.42%
1Y Performance:
+41.43%
1-Day Range:
$173.73
$177.80
1-Week Range:
$162.60
$182.99
52-Week Range:
$95.49
$182.99
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
176.93 | 10.68B | 4.09B | -404.84M | 1.24B | -6.7469 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
A Look at Jazz Pharmaceuticals's Valuation After Landmark HERIZON-GEA-01 Ziihera Trial Results - simplywall.st
Why Jazz Pharmaceuticals plc (J7Z) stock remains stableEarnings Performance Report & Verified Short-Term Plans - newser.com
What MACD trends signal for Jazz Pharmaceuticals plc (J7Z) stock2025 Winners & Losers & Capital Efficiency Focused Ideas - newser.com
How strong is Jazz Pharmaceuticals plc stock balance sheetJuly 2025 Levels & Real-Time Stock Movement Alerts - newser.com
Jazz Pharmaceuticals Insider Sold Shares Worth $3,259,538, According to a Recent SEC Filing - MarketScreener
Cozadd Bruce C, director at Jazz Pharmaceuticals, sells $3.2 million in stock By Investing.com - Investing.com South Africa
Insider Sell: Rick Winningham Sells 5,500 Shares of Jazz Pharmac - GuruFocus
Cozadd Bruce C, director at Jazz Pharmaceuticals, sells $3.2 million in stock - Investing.com India
Iannone, Jazz Pharmaceuticals EVP, sells $1.2m in JAZZ stock By Investing.com - Investing.com South Africa
Why Jazz Pharmaceuticals plc (J7Z) stock appeals to dividend investorsChart Signals & Entry Point Confirmation Alerts - newser.com
Is Jazz Pharmaceuticals plc (J7Z) stock undervalued at current priceQuarterly Growth Report & Stock Timing and Entry Methods - newser.com
Jazz Pharmaceuticals Insider Sold Shares Worth $1,204,573, According to a Recent SEC Filing - MarketScreener
Will Jazz Pharmaceuticals plc (J7Z) stock rise with strong economy2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
What technical charts say about Jazz Pharmaceuticals plc stockWeekly Gains Summary & AI Forecast for Swing Trade Picks - newser.com
No-Moat Jazz's Growth Supported by Positive Phase 3 Data for Ziihera and Strong Uptake of Xywav - Morningstar
Insider Sell: Robert Iannone Sells Shares of Jazz Pharmaceuticals PLC - GuruFocus
Iannone, Jazz Pharmaceuticals EVP, sells $1.2m in JAZZ stock - Investing.com India
Will Jazz Pharmaceuticals plc (J7Z) stock outperform benchmarksRisk Management & Weekly Chart Analysis and Guides - newser.com
Technical analysis overview for Jazz Pharmaceuticals plc stockTrade Risk Assessment & Growth Focused Entry Point Reports - newser.com
Visual analytics tools that track Jazz Pharmaceuticals plc performanceMarket Growth Review & Free Fast Gain Swing Trade Alerts - newser.com
Truist Adjusts Price Target on Jazz Pharmaceuticals Public to $220 From $205, Maintains Buy Rating - MarketScreener
Jazz Pharmaceuticals (JAZZ) Is Up 32.0% After Positive Phase 3 Results for Ziihera in HER2-Positive Cancer - simplywall.st
Can Jazz Pharmaceuticals plc stock resist sector downturnsWeekly Trade Review & Expert Verified Stock Movement Alerts - newser.com
Why Jazz Pharmaceuticals plc (J7Z) stock could be next leaderJuly 2025 Action & Community Consensus Picks - newser.com
Is Jazz Pharmaceuticals’ Rally A Buying Signal? - StocksToTrade
Single Trial Success Stories: UCB’s Kygevvi Joins US FDA Approvals With Confirmatory Evidence - Citeline News & Insights
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):